medic suppli devic
reason report
bottom line publish individu one-pag compani
preview cardio ew nvcn
large-cap diversifi diabetes/oth
pick necessarili specif remain large-
cap mid-cap small-cap given prefer
upward estim revis prospect quarter
backdrop basic stabl util trend neg
fx headwind could limit potenti ep upsid believ
quarterli result med-tech univers bias
in-lin modest upsid vs meaning downsid risk base
steadi util trend also think compani
like reiter guid head vs rais
specif cardio lean bit cautiou base
medacorp util survey gener less
bullish current go-forward volum growth trend said
compani midst strong new product cycl -- op
wathcman ew mp recent low risk approv
mp mitraclip label expans fare fine
context caution around cardio though favor
op head large-cap along ew specif
just-publish posit tavr transcathet aortic valv
replac medacorp survey result large-cap smid-cap
see upsid potenti sale share
op op op op -- stock
rel weak late
compani inform svb leerink llc research
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
rel high convict beat rais includ
expect deliv anoth strong beat valuat alreadi
double-digit ev/sal rang think share upsid might
limit deliv solid beat also might see
cap upsid given overhang caus recent short report
compani see risk print includ
expect tough quarter potenti miss
consensu sale growth project base recent medacorp
physician convers per recent impella survey note link
think downsid cap vs potenti
upsid
compani coverag univers either expect
larg in-lin print reason expect like caus
stock trade sideway beat rais beat
rais enough and/or stock reaction larg
predic clinical/launch updat includ
nvcn
svb leerink estim factset
quarter expect deliv basic in-lin quarter though modestli lower
sale estim line consensu recent lower sale estim reflect high-single-
digit growth believ reason given view compani recent initi
break barrier adopt next wave adopt take time also better reflect
fact compani face toughest y/i compar comp eas meaning back
half year actual wouldnt surpris see sale growth come even tad lower
base investor feedback expect come recent sell-sid confer compani
convers given stock declin month septemb seem investor
expect best in-lin quarter outright miss though believ
intern sale momentum could off-set bigger key stock move like whether
manag reiter sale growth guidanc -- think like
base alon much easier comp get particularli also acknowledg howev
regardless quarterli perform share could range-bound least year-end given
recent issu fact like near-term fix quarter despit histor trend
suggest rel flat vs even slightli better manag guid slight sequenti
declin sale due summer season toughest y/i compar still focus
manag commentari recent physician feedback recently-impl expand sale
forc vascular access train well come recent tct transcathet cardiovascular
therapi annual meet specif well look hear around recept physician
impella are/hav highlight skeptic around data clinic util devic
whether gain new implant recent month
recent note svb leerink leadership seri link podcast link note
quarter expect come toward low end manag organ sale
growth rang report sale possibl modestli miss consensu driven dramat fx
alin think itll tougher deliv upsid quarter given fx headwind
well seem base hospit util survey season slowdown cardiolog
procedur volum overal expect product like mitraclip deliv strong double-digit
growth given there reimburs coverag expand indic there still
pushback contradictori trial europ think may enough off-set season
slowdown cardio volum across area busi libr diabet estim sale
base iqvia script trend think alreadi reflect consensu
estim like put diabet sale larg line given believ like basic
in-lin sale perform ex fx need deliv meaning oper margin
out-performance weve seen last quarter and/or opex line benefit
possibl tax rate hedg gains/loss order beat ep us
consensu like leav guidanc organ sale growth unchang
manag need rais ep guidanc stock work print
view though believ ep beat like driven non-oper expens
think like rais ep guidanc print meaning rais last quarter
resultsactualestimatey/i growthconsensusvariancenet good gener administr develop ep region total segment total cardiovascular establish pharmaceut diabet compani report svb leerink estim factset visibl inc outperform price
quarter expect deliv sale beat vs us
consensu histor season trend hold would also repres growth
acceler quarter comp-adjust basi despit slower cardio volum overal
typic make sens us given cryospher ramp seem progress
faster initi expect continu ramp clip busi new product continu
roll steadi growth open busi mi busi wild card
believ estim reflect low expect potenti beat need deliv
y/i achiev current sale guidanc
therefor expect manag rais guidanc least reflect quarterli
beat see reason adopt trend slow current level low-double-digit
growth share level reaction recent
sentreheart acquisit short report think anoth quarterli beat rais
drive least partial recoveri share still quarterli result arent like fulli resolv
investor question rais around acquisit short report share arent like fulli
recov print key area interest call like focu clinic updat
notabl manag commentari sentreheart integr deal close
updat time thought converg anticip fda panel earli
follow-up complet august manag like saw data updat enrol
amaz trial expect regulatori pathway updat ice-afib deep-af enrol
on-going
recent note svb leerink leadership seri link podcast link note
quarter expect beat consensu above-consensu
estim meaning upsid view higher european util model
util growth sequenti vs q/q growth axnx r-snm continu
captur market share drive adopt snm therapi broadli increas awar
expect manag discuss implant volum market share europ manag
thought upcom competit mdt interstim micro anticip earli
expect competit vs axnx r-snm close featur gap regulatori updat
specif time approv larger oab overact bladder indic
late september/octob importantli updat fi fecal incontin launch
plan start ship r-snm end octob listen metric procedur
schedul earn call reflect underli demand overal though
stock vs ipo price think consecut sale beat enhanc
investor confid outlook european roll-out serv strong predictor
anticip launch us commentari around pend oab approv
critic driver stock share declin recent given lack approv close
fi approv ultim think oab approv matter believ
come day also acknowledg longer take come market shorter
near-term share captur opportun launch competit devic
recent note initi
quarter expect deliv basic in-lin sale anoth meaning ep beat
help continu sg optim base back-of-the-envelop analysi sale growth
trend see potenti upsid driven recent product launch
off-set impact brevibloc cyclo advanc surgeri anoth month
benefit competit suppli constraint pharma especi gener repres higher margin busi
rel corpor averag expect could drive meaning margin out-performance vs us
consensu promot manag rais full-year guidanc least reflect quarterli
beat key stock reaction specif perform medic deliveri given
investor concern compani abil ramp achiev oper
organ sale growth guidanc medic deliveri delta sale estim
ww ou consensu almost entir attribut ou
sale think estim may prove bit high think consensu
reason achiev given pace recoveri easiest comp y/i given
manag recent commentari intra-quart clearli confid oper sale
growth guidanc year busi outsid earn guidanc listen
manag commentari around recent medic deliveri market trend investor confus
follow competitor blame market fundament sale miss uptak expect adopt
recent pharma product launch includ myxredlin possibl updat clari warn letter
hope move past impact recent cheetah medic acquisit
appetit
recent note manag meet note svb leerink leadership seri link
podcast link note
quarter expect deliv basic in-lin revenu quarter toward lower end
organ sale growth guidanc rang ep high end guidanc
rang oper margin improv would repres growth acceler organ
would posit well reiter organ sale growth guidanc rang
year signific exposur cardiolog volum trend util survey
suggest trend weaker recent think out-performance key area like structur heart
medsurg off-set potenti downsid intervent cardiolog volum
broadli share weak recent neg headlin scope clinic trial ramp
investor fear sustain de volum trend ahead ischemia data
present aha american heart associ mid-novemb think reiter organ
sale growth ep guid view posit street outsid quarterli earn
think investor focu manag commentari around growth outlook peripher
intervent pi intervent oncolog btg updat eluvia paclitaxel-elut stent key
new growth driver fda recommend letter august categor paclitaxel issu
class effect neg scope data present tct transcathet cardiovascular
meet rais fear sale impact acur europ on-going lotu
ramp help off-set turnaround spinal cord stimul still clear definit
reason market slowdown
recent note svb leerink leadership seri link podcast link note tct updat
resultsactualestimatey/i growthconsensusvariancenet good gener administr develop ep region total baxter baxter product renal therapi deliveri surgeri baxter compani report factset consensu visibl alpha consensu svb leerink resultsactualestimatey/i growthconsensusvariancenet good gener administr develop incom ep region total boston scientif boston scientif product total rhythm boston compani report factset consensu visibl alpha consensu svb leerink inc outperform price
quarter expect deliv sale beat rang vs estim
y/i consensu base histor season trend continu ou
ramp would repres consecut quarter mid-teen sale growth
consecut quarter growth acceler comp-adjust basi reinforc investor
view manag drive growth acceler support solid growth core
peripher coronari busi supplement new revenu stream intern
ancillari support product like balloon guidewir expect beat think
manag like leav guidanc unchang given still earli year comp
get tougher throughout year reiter y/i sale
growth guidanc provid last earn call share ytd
think share could bounc beat particularli deliv anoth quarter sale growth
acceler comp-adjust basi beyond guidanc think manag highlight
key point earn call continu reinforc investor confid csii durabl
double-digit growth profil includ underli strength core busi dynam
seem shift toward obl office-bas lab altern access strong
competit advantag impact near-term pipelin specif support product
cad current pull-through rate cad busi drive increment
sale per procedur potenti pad support product start launch late fy
manag note increment revenu per procedur pad clinic trial
updat specif on-going enrol eclips enrol patient
last updat early-august on-going impact atherectomi recent fda
guidanc letter paclitaxel-elut product manag claim modest tailwind
quarter expect deliv yet anoth strong beat quarter somewher
rang vs us consensu wed expect actual closer base
histor season trend intern revenu also comp-adjust
basi assum momentum doesnt slow meaning assum beat primarili driven
 intern like come larg line vs consensu toughest y/i compar
expect manag rais sale guidanc least reflect
beat given recent share volatil inclin think risk/reward print
seem favor particularli given perceiv delay abt like libr
approv believ icgm still think linger libr concern could drive
continu volatil share investor clearer sens believ
limit impact dxcm abil drive continu adopt momentum beyond print
guid think investor focu commentari around evolv competit landscap
notabl abt libr could impact market dynam approv timelin slip
late time-frame timelin slip could mitig posit share
reaction strong print though also reason believ slip gm expans
new transmitt lower cog start roll manag impli
bp improv import compani actual deliv
major improv come order exit year continu success
manufactur capac expans manag note doubl year end
recent note svb leerink leadership seri link podcast link note
resultsactualestimatey/i growthconsensusvariancetot good gross gener administr develop ep region total breakdown total sensor durabl compani report svb leerink estim factset visibl edward lifesci corp ew market perform price
quarter expect ew recent medacorp tavr transcathet aortic valv
replac survey impli potenti beat thv quarter vs consensu y/i q/q
fall line consensu y/i q/q estim tavr market model assum
 tavr volum declin sequenti point market share shift favor op enter
tavr space lotu edg leav market share ew remain
mp compar survey project increas sequenti procedur volum growth ew
cede point market share quarter would impli upsid estim taken
togeth believ ew certainli benefit tailwind notabl august low risk approv
could make thv sale estim conserv continu ramp mitral sale upcom
product launch sapien ultra europ manag increas previous indic
thv sale guidanc post earn out-performance believ
recent survey suggest like prove conserv look beyond tavr consensu
surgic valv critic think might conserv critic also
see downsid surgic valv vs consensu particularli tavr clearli ramp better expect ultim
though stock move tavr out-performance like guidanc rais also like wed
expect share react posit quarter also think mitral perform quarter
import investor mitral repres next leg growth longer term current guidanc
reflect meaning back-half ramp vs would need start show
quarter expect report sale basic line estim consensu
consecut quarter miss guidanc reduct
sale estim declin y/i q/q assum declin domest sale y/i
q/q reflect smaller magnitud declin vs saw double-digit declin reflect easier
comp driven lower level purchas larg nation provid sinc septemb
meaning sequenti declin dtc domest sale q/q y/i reflect decreas
dtc sale rep headcount potenti improv rep product rep could lead work
base rough math believ sale rep headcount could y/i quarter anoth step
declin y/i think base histor season trend continu
improv product among season rep reflect low-single-digit project declin
basic in-lin expect manag leav full-year guidanc unchang importantli
compani follow histor preced expect manag issu guidanc call given recent
controversi around stock think manag like bracket estim y/i
consensu middl guid y/i rang expect focu
call driver return double-digit growth sustain growth beyond easier y/i
comp underli market demand success recent ne rep add potenti contribut recently-acquir
new aera expect minim ramp beyond ultim think one quarter
wont put investor fulli eas realli get stock move higher stock
year think sale growth guid least limit downsid
recent note svb leerink leadership seri link note
resultsactualestimatey/i growthconsensusvariancenet gener administr develop continu ep region domest product tavr corevalv tavr tavr transcathet aortic valv surgic heart valv critic transcathet mitral tricuspid ew compani report svb leerink estim factset visibl resultsactualestimatey/i growthconsensusvariancetot develop market administr incom ep domest domest direct sale compani report svb leerink estim factset visibl corpor outperform price
quarter expect deliv anoth solid quarter upsid estim
beat sever million least perhap high sale beat base season
trend new patient add also take account lower person diabet
manag revenu vs us consensu base calcul
appli normal season trend new patient add reorder revenu
 intern see broad-bas beat across busi though perhap
slightli skew signific adopt momentum clearli underfoot
would expect rais sale guidanc least magnitud beat
possibl rais low end rang meaning thu elimin seem
bear case scenario factor low end guidanc issu start
year solid beat rais like view believ print
repres anoth posit catalyst share even stock
ytd estim like move higher compani continu build track
record consist out-performance believ line sight durabl strong
double-digit profil becom increasingli clear would note howev anoth key
stock perform print reiter horizon ap timelin pivot
trial start eventu approv phone control
recent note svb leerink leadership seri link podcast link note
quarter expect kick med-tech earn season like set
investor expect quarter relat procedur volum trend overal
medacorp util survey hold expect convey basic stabl util
trend normal summer season longer provid specif hospit volum
growth trend quarter could make difficult use proxi med-tech
beyond orthoped vision specif expect see sale upsid vs
estim report come line consensu like
driven pharma also support stabl med-tech trend ep perspect
delta us consensu larg driven share count believ
continu share repurchas program believ beat consensu estim
like come line us higher sale vs consensu also slightli lower share
count vs consensu given move part includ gener competit zytiga
think manag reiter current guidanc organ growth ep
believ print investor focu chang
manag view abil deliv pharma growth zytiga gener headwind
success recent/upcom launch medic devic manag larg reli
return busi within broader market growth updat talc opioid liabil
assum risk tie on-going litig appetit ultim share
suffer litig overhang persist point better-than-expect result
shape year meaning sale ep growth acceler start
attract investor interest particularli increasingli volatil healthcar stock market
resultsactualestimatey/i growthconsensusvariancetot good gross gener administr develop incom cont ep overviewtot us omnipod omnipod deliveri revenu compani report factset consensu first order analyt svb leerink resultsactualestimatey/i growthconsensusvariancenet good gener administr develop incom continu ep region total product total medic devic consum compani report first order analyt visibl alpha consensu svb leerink plc market perform price
quarter expect deliv sale ep basic line estim
street impli organ sale growth
think itll difficult drive sale upsid base histor season trend even
recent new product launch gain momentum back-of-the-envelop math suggest
cardiovascular group cvg could deliv upsid realli back tavr
improv dcb drug coat balloon momentum post-fda guidanc issu earli august
think expect minim invas therapi group mitg could prove bit
aggress restor therapi group rtg diabet seem pois deliv
basic in-lin sale fx headwind also think margin upsid unlik
actual think consensu estim bp y/i margin improv may prove high
like deliv flat margin y/i still think key investor
reiter guidanc year -- organ sale growth suggest back half
acceler ep reiter key product launch timelin next
month diabet interstim micro rtg spring ultim
share alreadi ytd think earn rel non-ev
dont get sens investor expect beat rais expect miss
expect focu earn call abil drive sale growth
acceler longer term eventu return growth line med-tech market
sustain mid-single-digit underli fundament sustain near-term growth
outlook key busi like spine structur heart diabet appetit
recent note robot day note
quarter expect nvcn focu tiara clinic progress financi health
compani cash bank legal overhang remov
still compani cash posit like sustain develop less year
point manag hope posit reduc grow and/or partner
tiara much closer market nvcn recent report total number tiara
implant reach august vs may march novemb
august may march believ manag provid updat
clinic trial progress tiara hope see acceler enrol
site enrol clariti potenti time tiara trial complet nvcn
expect implant momentum acceler patient per month new center
come line total site target us key stock reaction
print reiter tiara timelin continu show progress trial
enrol beyond tiara reduc continu ramp nvcn ad sale rep
germani recruit anoth would total addit distributor
countri nvcn still engag fda final regulatori pathway explor
financ option initi cosira ii studi manag expect
clariti come month could get clariti well
resultsactualestimatey/i growthconsensusvariancenet good gener administr develop ep region total product cardiac vascular group therapi group mitg therapi group compani report factset consensu visibl alpha consensu svb leerink resultsactualestimatey/i growthtot good gross gener administr develop incom cont incl option compani report svb leerink corp outperform price
quarter expect deliv anoth quarterli sale beat would
second row new ceo keith grossman above-consensu sale
estim reflect believ probabl overli conserv assumpt nvro
abil sustain/gain modest market share ou spinal cord stimul
market sale estim repres declin y/i reflect nearli
point declin market share sequenti nearli point ou
acknowledg may modest downsid low-single-digit market
growth project even assum low-single-digit market declin quarter stabl
sequenti share us seem reason given recent turnaround
initi grossman put place seem take hold would suggest
sale upsid vs estim sale upsid vs consensu beat
wed expect manag rais sale guidanc current guidanc
alreadi suggest declin y/i back year meaning deceler
comp-adjust basi doesnt seem reason given recent success
turnaround initi implement potenti late-year launch next-
gen omnia platform flexibl waveform relat stock believ
risk/reward favor print addit believ
beat rais wed expect grossman provid posit commentari
market anniversari inventori impact well reiter recent success
effort reinvigor growth within seemingli posit compani
double-digit growth beyond
recent note svb leerink leadership seri link podcast link note
quarter expect basic line us consensu
factset compani good visibl ou sale distributor roch
variabl like come segment last quarter deliv
sale almost doubl nearli howev bridg program
continu expand like variabl sale perform base
time revenu recognit ultim though major sale continu ous-
driven would expect deliv posit commentari across key initi includ
posit coverag decis well way cover live
year underli demand evidenc expand bridg program end
updat progress convers secur medicar coverag expect
potenti time geograph expans new countri potenti come
line year ramp believ manag reiter goal
secur cover live year-end well sale guidanc
us key investor share pressur
late ytd also expect reiter timelin complet
promis trial studi sensor manag note enrol
complet expect come month august
recent note svb leerink leadership seri link podcast link note
manag meet note
resultsactualestimatey/i growthconsensusvariancetot good gross gener administr develop ep metricsend us breakdowndomest compani report factset consensu visibl alpha consensu svb leerink inc outperform price
quarter expect beat us y/i sequenti declin
q/q consensu potenti upsid driven ou
adopt momentum compani continu roll slim pump basal-iq
technolog current sale estim assum pump shipment
 slight sequenti growth qoq pump ship
pump shipment intern signific step-down
fulfil backlog contribut out-performance expect
manag rais sale guidanc print investor larg
expect beat rais think strong intern quarter beat view
particularli posit investor bulk anima convers intern
work investor first look core underli growth
momentum could go forward ex-u could give level visibl
comfort sustain growth momentum also think
importantli need reiter timelin control iq launch
critic compon sustain adopt momentum go forward ultim
share larg rang bound rang sinc print larg due
concern around tough comp head think intern ex anima
datapoint import investor
recent note svb leerink leadership seri link podcast link note
manag meet note
quarter expect deliv upsid current estim
y/i street driven ramp maci adopt trend compani continu
train surgeon util new exist center continu ramp
model current assum exit train surgeon includ new
surgeon train quarter vs train per quarter util
procedur per surgeon vs estim us leav plenti room
upsid epicel sale volatil natur model slight sequenti growth vs
lumpi busi highli unpredict real histor trend follow
ultim think current guidanc y/i y/i
conserv like beatabl inclin think manag like
rais guidanc least beat share recent high
like due investor concern around burn busi think share attract
increas investor interest anoth beat rais quarter particularli compani
deliv anoth solid quarter epicel result busi seem stick
point right investor concern impact possibl
competitor expect deliv gross margin vs
compani drive leverag ramp volum
recent note svb leerink leadership seri link podcast link note
resultsactualestimatey/i growthconsensusvariancetot gross gener administr develop ep metricsnew breakdownu revenu suppli revenu revenu compani report svb leerink estim factset visibl resultsactualestimatey/i growthconsensusvariancetot develop gener administr incom ep breakdowncarticel maci revenu mediwound profit share compani report factset consensu first order analyt svb leerink medic suppli devic
rate share outperform price target us
much execut stori compani continu drive adopt impella famili
percutan ventricular assist devic pvad enter next phase
adopt curv admittedli like multi-quart turnaround requir heavi
lift compani still believ double-digit growth sustain even
period transit compani like retain monopoli us heart recoveri
market opportun forese futur time-frame project
sale compound-annual-growth-rate drive adopt current high-risk pci cardiogen shock
indic
highli under-penetrated market opportun penetr
base abmd market assess address patient includ
cardiogen shock patient high-risk pci patient right heart failur
patientsal believ remain intact
geograph expans germani japan manag estim
penetr address patient germani still earli commerci
roll-out address patient market opportun japan
clear strateg plan break barrier adopt motto train data
time compani continu train physician build clinic data still
balloon pump use cardiogen shock patient today compar
estim impella implant given balloon pump
deem class devic countri like germani japanmean
actual caus harm usedit seem clear us technolog eventu becom
obsolet impella viabl replac believ barrier adopt
gradual broken awar spread still-build clinic dataset
train continu ramp
believ drive solid double-digit sale growth exist cardiogen
shock high-risk pci indic view potenti indic expans stemi
st-elev myocardi infarct could ultim doubl exist total
address market todaya call option compani recent receiv
fda approv initi stemi triala prospect multi-cent two-arm trial plan
enrol patient undergo treatment stemi heart attack enrol begin
octob expect finish date time frame
beyond double-digit sale growth monopoli pvad space also offer one
compel margin profil coverag univers gross margin
oper margin leverag ultim push oper margin
believ repres uniqu asset smid-cap med-tech
price target appli ev/sal multipl sale
estim assum current sale multipl hold steadi believ upsid
share near term limit beat rais difficult come
light potenti slower ramp adopt next wave adopt requir focu
effort part compani drive adopt
risk rate valuat includ failur drive increas util rate
and/or continu add new account steadi rate failur execut pipelin
launch new geographi potenti reimburs declin potenti competit
pvad product secur approv gain meaning market share potenti
rate share market perform price target abbott
like drive market growth key product launch believ margin expans
continu remain key piec abbott long-term invest thesi abbott also
attract investor look safer defens stock healthi dividend yield
current increasingli volatil market help sustain
current multipl abbott succeed drive meaning margin expans nutrit
busi margin mid-teen level post-split still go
increas cost effici suppli chain manufactur abbott pipelin also
number product launch broader rollout includ alin roll-out indic expans
mitraclip function mr mitral regurgit freestyl libr view abbott
like less acquisit immedi term follow two larg acquisit
remain sidelin given valuat rel still-high expect uncertainti
potenti sale upside/increment margin expans level
expect share trade assum multipl ep
estim basic line large-cap med-tech group
clearli pois drive above-market sale growth next year believ current
valuat alreadi reflect high convict consist beat
rais stori potenti execut risk around new product launch --
heavili depend notabl freestyl libr mri-saf high power devic -- see
opportun potenti downsid vs meaning clear-cut upsid
risk includ potenti slow end-market growth and/or increas competit
major product includ abbott xienc de total current abbott sale product
recal manufactur warn letter could push oper cost higher hinder sale
growth success pipelin execut key abbott growth stori product
approv time approv becom increasingli uncertain today challeng
regulatori environ success execut margin expans opportun
environ increas price pressur potenti acquisit could dilut
rate share outperform price target
believ well-posit sustain double-digit top-lin growth least
next year
core open ablat busi make sale -- well-posit
deliv sustain least high-single-digit growth forese futur guidelin
chang acceler growth drive ablat penetr open cardiac procedur
increas awar among clinician beyond open ablat busi atrc core
atriclip also repres sustain double-digit growth opportun overal grow
awar benefit close appendag
long-term growth perspect continu advanc mi minim invas
ablat pipelin could ultim open multibillion-dollar atrial fibril af
ablat market opportun address atrial fibril patient
 like meaning acceler growth longer term upcom converg
mi launch late time-frame manag expect releas converg
data head anticip fda panel meet fda approv like
time-frame view major catalyst next month
beyond atrc core busi mi pipelin converg deep
procedur acquisit sentreheart lariat expand product offer
electrophysiologist ep could highli complementari atrc converg
next month believ share trade appli
ev/sal multipl revenu estim assum stabl multipl
current level ev/our estim still modest discount
smidcap med-tech coverag univers avdr ev/
sale given sale growth acceler march toward profit think
ev/sal multipl justifi
risk includ failur success execut surgeon train new af indic
adopt concomit surgic ablat clinic trial delay failur demonstr
superior converg trial ou regulatori delay
rate outperform rate price target us axon repres
hyper-growth stori clear pathway profit smid-cap med-tech current
project sale compound-annual-growth-rate sustain net profit key
growth driver commerci r-snm overact bladder oab
fecal incontin fi symptom syndrom defin urinari bowel incontin
estim repres market opportun patient recent axon secur
approv r-snm fi smaller indic approv oab still pend
believ oab approv matter particularli given fda willing approv
fi repres key value-driv near long term fda
approv oab expect day fi believ axon
abl drive robust adopt compani execut commerci effort
 intern beyond overal view two-prong growth
near term rapid adopt like larg driven share gain next
month previous singl player market axon pois win product
differenti longer-wear recharg smaller mri-saf vs competit
seem address patient physician barrier adopt exist today
beyond long-term growth stori potenti snm market expans driven
greater awar continu innov two player market
meaning product innov didnt exist previous
near term also view upcom fda approv meaning catalyst
share along like estim upsid r-snm continu roll europ undertak
next month believ share trade arriv valuat
use discount cash flow dcf compar compani ev/sal analysi
dcf arriv valuat impli ev/sal
trade estim sale estim
repres discount view compar higher-growth small-cap med-tech group
consist op nr op nr op nr
nr nr op current trade sale estim
sale estim averag appli group averag sale
sale sale estim respect
compar valuat put axnx pt rang given view strong
ramp adopt eu launch bode well upcom commerci believ
axon hyper-growth trajectori support valuat least line group averag
risk share includ failur build success sale forc drive awar
and/or continu add new account failur drive increas util r-snm
upcom competit mp launch next-gen interstim failur drive
market expans potenti smaller-than-expect address market
rate share outperform price target believ sale
growth acceler stori remain underappreci street bax lrp sale
compound-annual-growth-rate time-frame oper margin ramp
immedi post-spin us well-posit
exit lrp long-rang plan near top-lin growth organ ahead
overal med-tech market mid-single-digit rang possibl even faster growth overal via
given compani solid execut to-dat steadi stream upcom new product launch
addit clari fill gener inject busi increasingli confid
continu drive upsid current long-term growth margin target
believ margin expans stori alreadi least partli price stock
manag current guid oper margin
see room upsid margin ramp believ major upsid
alreadi price share level
sale perspect also see potenti upsid current top-lin growth target
compound-annual-growth-rate time-frame driven new product launch geograph
expans someth feel underappreci street pipelin biggest
driver sale growth acceler next five year expect launch
new product new product expect make total sale
ramp expect signific growth pd periton dialysi gener
inject biosurgeri core growth contributor drive top line grow
solid mid-singl digit higher
addit strong free cash flow gener capabl free cash flow target
vs potenti upsid free cash flow view
increas financi flexibl invest busi drive even faster sale
growth acceler invest inorgan outsid opportun supplement top-
bottom-lin growth
overal find bax margin expans stori compel believ investor
underappreci bax sale growth reacceler stori also compani cash-
gener capabl believ ebitda repres relev
measur valu compani vs price earn combin
discount cash flow analysi ev/ebitda ev/fcf arriv price
next month believ share trade
rang dcf valuat deriv base case upsid scenario
supplement ev/fcf ev/ebitda analys price-to-earnings perspect pt impli
multipl ep estim repres modest multipl expans
current level pe ep modest discount price-to-earnings
large-cap med-tech group sale growth acceler
think multipl expans group averag justifi
risk includ failur execut margin expans initi new product launch delay
possibl acquisit either dilut perceiv further baxter growth goal
could pressur stock
rate share outperform price target believ
repres one attract top- bottom-lin growth stori large-cap med-tech
best-in-class product portfolio pipelin drive organ growth acceler
continu margin expans drive double-digit ep growth given compani best-
in-class product portfolio pipelin drive organ growth acceler
increasingli confid well track achiev long-term goal laid
june analyst meet includ sustained-to-acceler revenu growth --
compound-annual-growth-rate time-frame vs time-frame
continu target bp oper margin expans per year
double-digit ep growth driven sale growth continu oper leverag
strong gener compound-annual-growth-rate greater flexibl capit
deploy believ togeth solidli posit deliv double-digit ep growth
next year alreadi well track view achiev long-term sale
growth goal manag indic confid sustain recent pipelin
commerci execut continu roll-out sever key new product launch
meaning contributor top bottom line includ limit
watchman left atrial appendag closur devic continu roll-out exceed
expect lotu edg roll-out eu well continu adopt
acur valv sustain above-market growth medsurg driven market-lead
posit pipelin product coupl acquir asset includ milliped
nxthera cameron health posit increment sale growth acceler leav
potenti upsid current project sale compound-annual-growth-rate
number key litigi issu settl significantli fewer call cash
give manag first time ever significantli greater flexibl deploy capit
potenti ramp inorgan invest
next month believ share trade deriv appli
price-to-earnings multipl cash ep estim price-to-earnings
high-singl digit rang healthier balanc sheet modest premium justifi
compani continu deliv solid execut consist meet-or-beat quarter
also ramp key new product move past litig issu
risk includ lack meaning recoveri med-tech market broadli major boston
scientif market drug-elut stent de cardio rhythm monitor
specif failur success execut key new product launch major litig
loss potenti product recal particularli within inabl suffici reduc
cost drive oper margin expans
rate inc share outperform
month price target broader pipelin distribut agreement orbusneich
transit single-product single-geograph compani multi-product
multi-national compani deep pipelin ultim provid complet toolkit
manag outlin plan goal achiev revenu
repres sale compound-annual-growth-rate driven core growth
address highli under-penetrated market peripher coronari
geograph expans expect bring sale total sale
robust pipelin plan new product time frame
could potenti contribut sale total sale
acknowledg execut risk given relianc new product launch contribut nearli
sale still believ ambiti long-term guidanc compound-annual-growth-rate
achiev given revamp manag team proven track record
execut success oper acumen core busi continu believ
compani signific competit advantag calcifi below-the-kne lesion within
peripher drive above-market growth well grow market-lead
posit highli under-penetr coronari market us project long-term
growth core pad cad busi leav room upside/offset execut risk
new product launch
price target appli ev/sal multipl sale estim
reflect stabl multipl current level ev/sal multipl
sale still smid-cap coverag univers averag
reflect new product-rel execut risk
market share potenti product recal failur dcb drive atherectomi adopt
rate inc share outperform price target
continu believ remain path consist beat rais time
come driven market seem pois potenti doubl next
year today dxcm market-lead posit continu build
momentum near medium term despit competit headwind anticip next-
gen launch reduc form factor improv ease-of-us
meaning lower cost us seem particularli well-posit best-in-class
statu fda industri work dilig toward ultim goal develop artifici
pancreasessenti cgm-augment insulin pump system automat accur
next month believ share could trade appli
ev/sal sale share current trade
sale premium compar smid-cap med-tech compani
nxtm believ continu deliv estim
upsid sustain ev/sal multipl current level ultim believ share
warrant least modest premium small-cap med-tech stock univers given
massiv highli under-penetrated total address market consist upsid
potenti top-tier growth outlook longer term
risk includ failur continu evolv sensor technolog includ verili product
type patient toward sensor-integr pump potenti price pressur
increas competit potenti product recal reimburs issu
rate edward lifesci nyse ew share market perform
price target edward current market leader tavr transcathet aortic
valv replac market intern continu believ tavr
repres one excit new med-tech market high-teen higher
project market compound-annual-growth-rate time-frame base estim sens
ramp less sick patient popul intermedi low risk occur
slower pace already-elev investor expect continu believ
intermedi risk -- low risk -- indic repres massiv increment market
opportun also believ ramp patient slower saw
inoper high risk low risk ramp like even slower seen
term need seemingli intens market develop effort drive referr
move risk curv particularli younger less sick portion intermedi
risk patient popul low risk patient popul potenti increas surgeon
pushback less sick patient popul heart member ramp effort
preserv surgic busi
near-to-medium term ew still beat rais stori share current trade
earn becom increasingli difficult argu meaning multipl
expans
price target appli price-to-earnings multipl ep estim
pt assum stabl multipl current ep estim
large-cap group averag also think ew market-lead posit
highli under-penetrated total address market justifi premium valuat rel
rest large-cap med-tech group mp op mp op
risk includ inflect point intermedi risk adopt ramp neg competit
clinic data and/or competit launch delay faster-than-expect low risk
asymptomat trial ramp earlier-than-expect cardiaq feasibl trial re-start
rate share market perform mp price target view
differenti technolog competitor larg under-penetr long-term oxygen
therapi ltot market manufactur market portabl oxygen concentr
poc that gener view best-in-class base efficaci size allow superior
portabl patient mobil compani also implement uniqu direct-to-consumer- dtc
sale strategi despit well-known reimburs headwind protect profit
margin still allow higher invest versu competitor
time-frame project deliv sale compound-annual-growth-rate
poc therapi class expand within ltot given favor demograph broaden
awar earlier diagnos underli condit copd longer life
expect oxygen therapi
inogen drive continu market share gain within poc increas awar
barrier adopt poc broadli compani inogen one specif exist
includ lack awar poc inogen one potenti higher
up-front cost patient versu tradit oxygen therapi awar continu grow
compani continu invest build sale forc dtc market effort
word mouth take hold cost frequent cite issu medacorp
physician survey spoken continu technolog improv higher
patient invest therapi decis could help mitig barrier
pt appli ev/sal multipl sale estim
look med-tech compani similar sale growth gross margin profil
nr nr mp nr nr nr nr nr
think might repres reason valuat compani
firmli re-establish consist beat rais compani strong double-digit
growth margin improv opportun near-to-medium term think tough
argu multipl expans current level sale particularli lack
convict hold upsid potenti estim next month
risk share includ account issu possibl greater reimburs cut
current model loss increment competit bid contract exclud
compani access new patient potenti competitor replic implement
compani dtc strategi inabl build awar drive increas penetr
poc oxygen therapi market
rate share outperform price target johnson johnson
histor repres defens stock view johnson johnson also
repres growth acceler stori beyond compani continu
execution-driven turnaround medic devic consum busi offset
pharma patent expir robust growth core drug new launch continu
believ johnson johnson drive sustain organ mid-single-digit top-lin growth
even better high-single-digit bottom-lin growth long-term help strong growth
core new drug stelara tremfya imbruvica darzalex continu
innovation/in-licens re-launch babi brand consum continu
improv medic devic busi ultim return sustain solid mid-
single-digit top-lin growth trajectori potenti above-market growth
dividend yield strong free cash flow gener believ share repres
attract total return vehicl investor
next month believ share trade price target price
target appli price-to-earnings multipl ep estim share current trade
ep estim large-cap med-tech group rang
price target assum see multipl
expans line broader comp group compani manag top-
line headwind continu drive oper leverag -- posit
sustain ep out-performance view total return capabl attract
increasingli volatil stock market environ like attract fund riskier area
risk includ failur success integr auri potenti futur acquisit failur
resolv outstand consum consent decre success re-launch product
product recal failur advanc late-stag pipelin success launch
new product protract recoveri procedur volum trend lack real
rate share market perform price target believ
return mid-single-digit top-lin growth trajectori eventu nearli total
sale cardiac rhythm manag spine market estim grow
low-single-digit best mdt sustain growth trajectori larg predic
recent upcom new product launch well success integr covidien
largest acquisit compani histori
ceo omar ishrak helm clearli focus control cost help off-set
on-going price pressur slow market growth broadli med-tech excis tax
name see opportun margin expans combin compani
attempt extract signific cost synergi though compani continu make progress
time extent margin improv still remain challeng increas fx pressur
despit earli sign market stabil market growth recoveri coupl
continu soft spine inclin remain sidelin share
pend clariti execut upcom new product launch help stem
market share loss spine drive market share gain busi
success deliv increment margin expans beyond cov synergi
major med-tech market broadli spine specif experienc real
price target appli price-to-earnings multipl ep estim
assum share sustain current multipl ep estim
though believ could eventu return path consist mid-
single-digit top-lin growth -- rtg big piec growth acceler -- remain
sidelin pend clariti cvg sale abil absorb/mov
past on-going headwind ramp key pipelin product surgic robot
minim invas therapi group mitg time less certain see limit multipl
expans mid-single-digit growth trajectori larg predic new
product launch sustain trend without risk
risk valuat includ continu signific spine market spine sale declin
market fail regain momentum greater-than-expect drug elut stent de market
share loss greater infus sale declin failur deliv product pipelin failur
success execut cost save initi
rate nvcn share outperform price target though still earli
develop believ neovasc verg tap dramat larg
potenti high growth transcathet mitral valv replac tmvr market tiara
technolog neovasc tiara current forefront still nascent develop
market total number implant reach patient either feasibl
compassion use mitral regurgit mr preval aortic stenosi
tmvr clearli repres massiv virtual unpenetr market opportun peg
global tmvr market opportun assum tmvr initi target function mr patient
high risk surgeri almost tripl current transcathet aortic valv
replac tavr market estim use tavr proxi clear demand
less invas transcathet therapi high valvular diseas patient mr particularli
sever mr repres highli underserv patient popul poor surgic outcom
drive surgic penetr rate less total market tiara clearli
without risk given earli stage develop medacorp physician check suggest
tiara repres highli viabl solut given anatom d-shape leaflet independ
next month believ nvcn share trade arriv price target
use discount cash flow dcf analysi take averag valuat base rang
royalti rate dcf use discount rate probability-
weight price target reflect averag believ possibl royalti rate
rang royalti pay-out conserv scenario view
acknowledg small-cap med-tech compani valu base compar compani
ev/sal multipl believ dcf best captur total address market opportun
neovasc tiara tmvr market estim potenti global
risk neovasc rate valuat includ possibl tiara and/or reduc
approv us and/or europ commerci ramp tiara and/or reduc fail
meet expect challeng fda approv pathway tiara and/or reduc
fairli robust competit landscap mr replac pipelin on-going trademark
potenti patent litig potenti reimburs risk failur obtain suffici
reimburs tiara and/or reduc secur approv
rate share outperform price target
new ceo keith grossman right ship view execut stori
manag team stabil strengthen compani commerci foundat
optim commerci potenti transit year grossman
revamp process think return double-digit sale growth
beyond given
underli market continu deliv solid volum growth
abl return share gain posit rep product ramp
improv within commerci infrastructur specif salesforc
upcom omnia launch expect drive increment growth
longer term continu believ market grow solidli
double-digit rang increasingli well-posit grow even faster
remain one compani focus indic expans clinic data
next month believ share trade appli ev/
sale multipl sale estim assum stabl multipl vs current
estim basic line small-cap med-tech
coverag univers ev/sal
risk share includ difficulti shift physician adopt away current
cut potenti high frequenc competit anoth major player could impact
long-term market share and/or forc enforc intellectu properti ip right
like time-consum expens effort increment reimburs cut may
pressur price longer term
rate share outperform price target next year
continu focu drive strong referr momentum expand access
greater awar deliv believ around nearli top-lin
compound-annual-growth-rate time-frame underw manag transit sever
year ago busi stabl to-acceler believ long-term market
opportun pump therapi improv seem adopt inflect
solid execut continu reinvest sale forc appear pois
next month believ share trade pt appli
ev/sal multipl sale estim share current trade
sale estim expect multipl hold current level given
believ sustain double-digit growth next year dramat
improv profit profil -- consist net incom posit believ share
deserv trade premium ev/ sale multipl smid-cap med-tech
risk includ failur success execut adopt omnipod type patient
potenti manufactur issu and/or inabl seamlessli ramp product failur
advanc pipelin artifici pancrea product failur bring success drug
deliveri partnership commerci increas competit higher us dollar
rate share outperform price target believ senseon
verg dramat sale inflect point continu roll eversens
implant continu glucos monitor cgm wear europ
 cgm penetr insulin-depend patient believ
global cgm market still much earli stage adopt increas awar
improv reimburs continu technolog evolut longer-wear
implant sensor senseon eversens play key role like continu drive
rapid growth via expand patient popul eventu aggress
penetr beyond type much-larg multi-million type patient popul
view eversens appeal broad patient popul encompass type
current declin cgm option due high burden therapi patient also
type reason us posit compani dramat top-line growth
next year clear path profit
modest penetr type margin penetr insulin-depend
type believ senseon deliv compound-annual-growth-rate time-frame
ramp sale see potenti upsid
estim driven
on-going launch eversens sensor beyond
continu roll-out eversens xl rest europ
beyond solid execut drive sale inflect anticip launch
eversens xl sensor end next major catalyst addit
sensor develop would competit differenti gap
next month believ share trade appli ev/
sale multipl sale ev/sal sale
pt reflect confid potenti adopt trajectori given posit earli feedback
europ best-in-class mard mean absolut rel differ ramp line
better expect
risk share includ difficulti shift physician adopt away current
tradit cgm therapi increas competit counter-detail failur build
success sale forc train physician drive adopt failur advanc
pipelin includ sensor expand indic pediatr
rate share outperform price target believ
current adopt inflect diabet devic insulin pump cgm
continu glucos monitor believ specif major driver adopt
inflect recent slim basal iq launch driven higher patient switch
anima also ramp new patient add mdi multipl daili inject user
partner best-in-class cgm develop differenti pump platform
remot upgrad easy-to-us touch screen well compani mid-term
commit launch one new product per year believ built ever-widen
competit moat major durabl pump player put
posit continu drive patient switch beyond patient switch constitut
tndm patient add tndm ease-of-us posit basal iq patient experi
success manag diabet also driven acceler adopt among mdi
dynam see sustain forese futur
longer term view pump market opportun compel target larg grow
under-tr patient popul diabet estim world-wide type
believ posit within type market drive market share gain via
patient switch also bring new patient onto pump therapi untap opportun
market estim insulin-depend type tndm instal
base type see sustain strong double-digit sale grower
forese futur even potenti upsid project compound-annual-growth-rate
time-frame meaning ahead consensu out-year
believ much above-street estim out-year due believ
key mispercept among analyst investor believ insulin pump market growth
acceler mid-single-digit previous sustain double-digit growth
see potenti even upsid modest penetr type
margin penetr insulin depend type increas adopt driven continu
product evolut includ tndm upcom slim control iq launch
beyond like continu estim upsid share could move even higher driven
control iq launch believ could drive yet anoth adopt inflect
continu clinic updates/progress next-gener sport expect
launch eventu phone-control help acceler
new patient add mdi patient potenti even ramp adopt insulin-
next month believ share trade arriv valuat
use discount cash flow dcf compar compani ev/sal analysi
valuat appli ev/sal multipl sale estim assum
stabl multipl current level sale repres premium
view compar higher growth small-cap med-tech group current trade
profil clear pathway profit support valuat ev/sal rang
especi given financi overhang remov result equiti rais
improv free cash flow pictur
risk share includ increas competit pump market failur drive
oper leverag failur execut drive insulin pump penetr
rate share outperform price target believ
maintain virtual monopoli highli under-penetrated articular cartilag repair market
could ultim see open-end growth longer term recent launch maci product
repair larg cartilag defect seen sale growth acceler
mid-single-digit third-gener product
launch broadli one-of-it kind amount support clinic data
includ summit trial demonstr superior vs standard care microfractur
year carticel use first-gener product maci procedur base
 eas use faster rehabilit time increas appeal physician
orthoped surgeon special sport medicin patient physician train
util maci continu ramp believ deliv least maci sale
growth next three year mid-teen growth sustain go-forward basi
high end compar small-cap med-tech compani coverag univers
see signific opportun upsid alreadi above-street estim driven
even higher number orthoped surgeon util maci total
target orthoped surgeon perform high volum cartilag repair procedur
model current assum surgeon train exit
higher util new exist surgeon maci ease-of-us benefit well
shorter rehabilit time could drive surgeon use even frequent saw
carticel current estim estim maci procedur per
surgeon per quarter project util drop slightli
continu train new surgeon
sever burn market also market autolog epiderm product address
penetr believ epicel alon sustain high-single-
digit low-double-digit grower addit recent announc licens agreement
mediwound nexobrid -- biolog orphan drug product debrid sever thermal
burn -- highli complementari synergist epicel busi nexobrid expand
sever burn portfolio debrid expand total address market
hospit burn patient bring increment market opportun current
epicel today per manag estim
favor gross margin profil variabl cog total
well-posit significantli expand gross margin ultim achiev sustain
oper incom net profit earlier
next month believ share trade pt appli
ev/sal multipl sale estim assum modest multipl
expans current level sale top-tier growth profil
monopoli larg under-penetrated market path profit believ share
deserv trade least line ev/sal multipl higher-growth smid-cap
risk valuat includ inabl execut physician train drive ramp
maci adopt potenti product recalls/regulatori issu either maci epicel
competit entrant current unawar need rais addit capit
reach profit could dilut exist sharehold inabl optim
variabl cog control oper expens order drive posit leverag
dollar million except per share data
total good sold
research develop expens
cog sale
sg sale
 sale
oper expens sale
compani report svb leerink estim
dollar million except asp
good sold
research develop expens
pre-tax incom continu oper
sg sale
 sale
oper expens sale
compani report svb leerink estim
dollar million except per share amount
product sold
research develop expens
cog sale
sg sale
 sale
oper expens sale
compani report svb leerink estim
dollar thousand except per share amount
sold
research develop expens
gener administr
 sale
 sale
 sale
oper expens sale
compani report svb leerink estim
dollar million except asp
good sold
research develop expens
pre-tax incom continu oper
sg sale
 sale
oper expens sale
compani report svb leerink estim
dollar million except per share amount
good sold
research develop expens
pre-tax incom continu oper
sg sale
 sale
oper expens sale
compani report svb leerink estim
dollar thousand except per share amount
product sold
research develop expens
cog sale
sg sale
 sale
oper expens sale
compani report svb leerink estim
dollar million except per share data
good sold
product good sold
develop good sold
total good sold
research develop expens
sg sale
 sale
oper expens sale
compani report svb leerink estim
dollar million except per share data
good sold
research develop expens
pre-tax incom continu oper
incom continu oper
sg sale
 sale
oper expens sale
compani report svb leerink estim
dollar thousand except per share amount
sale revenu
rental revenu
sold
research develop expens
 sale
 sale
 sale
oper expens sale
compani report svb leerink estim
dollar million except per share data
good sold
research develop expens
pre-tax incom continu oper
net incom attribut non-controlling
net incom attribut
sg sale
 sale
oper expens sale
compani report svb leerink estim
dollar million except per share data
good sold
research develop expens
pre-tax incom continu oper
net incom continu oper
earn discontinu oper net tax
net incom attribut non-controlling interest
net incom attribut
sg sale
 sale
oper expens sale
revenu report
oper revenu ex fx divestitur
compani report svb leerink estim
dollar million except ep
good sold
loss foreign exchang
basic averag share million
good sold sale
sg sale ex med-tech tax
 sale
oper expens sale
good sold
basic dilut ep
compani report svb leerink estim
dollar million except per share data
total good sold
research develop expens
net incom compani
accret redeem convert prefer stock
cog sale
 sale
sg sale
oper expens sale
compani report svb leerink estim
dollar million except per share data
total good sold
research develop expens
loss discontinu oper
sg sale
 sale
oper expens sale
compani report svb leerink estim
dollar thousand except per share data
good sold
accret redeem convert prefer stock
net loss attribut common stockhold
dilut averag share thousand
good sold sale
sg sale ex med-tech tax
devic tax sale
 sale
oper expens sale
good sold
net incom cont op
compani report svb leerink estim
dollar million except per share data
total good sold
research develop expens
loss extinguish debt
chang fair valu stock warrant
oper expens sale
compani report svb leerink estim
sg sale
 sale
dollar thousand except per share amount
sold
research develop expens
impair intang asset
increas decreas fair valu warrant
 sale
sg sale
oper expens sale
compani report svb leerink estim
